HCA Healthcare, Inc. (HCA) — Executive Summary HCA Healthcare, Inc. operates a large U.S. hospital and healthcare services network and presents as a capital‑intensive, cash‑generative company with strong multi‑year EPS compounding and steady revenue growth. The company’s multi‑year growth profile is a clear strength: 5‑year EPS compounded at 19.20% and revenue per share rising at a 7.51% CAGR, wit
HCA Healthcare, Inc. operates a large U.S. hospital and healthcare services network and presents as a capital‑intensive, cash‑generative company with strong multi‑year EPS compounding and steady revenue growth.
The company’s multi‑year growth profile is a clear strength: 5‑year EPS compounded at 19.20% and revenue per share rising at a 7.51% CAGR, with the most recent revenue‑per‑share level at $321.47 and year‑over‑year growth of 7.1% (see EPS Diluted & Revenue per Share and Revenue & EPS Growth).
Profitability on a net basis has been durable, with a reported net margin around 11.84% and a trailing‑twelve‑month return on equity that stepped up to 14.1% (2021), supporting the company’s ability to convert earnings to shareholder returns (see Profit Margin Trends and Return on Equity (ROE)).
Cash quality also looks strong on historical metrics: operating cash flow has exceeded net income on a multi‑period basis (cash conversion ratio 1.9561), and operating cash flow TTM was reported at $5.45B in the available series (see Earnings Quality Analysis).
Notable areas of concern include near‑term liquidity and allocation of capital. The current ratio is below 1.0 at 0.8335, indicating tighter short‑term liquidity (see Strategic Capital Allocation).
Financing cash flow has shown increasing outflows, with Financing Cash Flow (TTM) moving to –$8.55B by 2025‑12‑31, which represents a pronounced increase in financing outlays versus earlier periods (see Strategic Capital Allocation).
There is also a divergence in the most recent comparable observations between net income ($6.96B TTM) and the most recent reported operating cash flow ($5.45B), narrowing the previously favorable cash‑conversion relationship (see Revenue & Net Income and Earnings Quality Analysis).
See Profit Margin Trends, Earnings Quality Analysis, Strategic Capital Allocation, Revenue & EPS Growth, and Price-to-Earnings (PE) Ratio Trend for the supporting series.
The foundation of business quality and long-term value creation
HCA Healthcare, Inc.'s recent quarterly revenue has been concentrated around the high‑teen billions. Quarterly receipts were $19.08B in 2025‑03‑31 and $19.11B in 2026‑03‑31, with intervening quarterly reports at about $20.14B (2024‑09‑30). Reported period totals labeled at year‑end show larger aggregated figures — $56.52B (2025‑12‑31), $50.46B (2024‑12‑31), and $64.97B (2023‑12‑31) — while the most recent quarter remains near $19.1B.
Net income for HCA Healthcare, Inc. has trended upward in the most recent quarterly observations, rising from $1.59B (2024‑03‑31) to $1.65B (2025‑06‑30) and $1.86B (2026‑03‑31). There are earlier, larger year‑end net income observations in the dataset (for example $4.69B at 2021‑12‑31 and $3.09B at 2020‑12‑31) that stand out relative to typical quarterly results. The most recent quarterly revenue was $19.11B. The most recent quarterly net income was $1.86B.
Why Growth Matters
Consistent revenue and earnings growth are the lifeblood of successful long-term investments. Companies that can grow their top line (revenue) and bottom line (net income) over many years demonstrate they have products or services customers value and are willing to pay for repeatedly.
Revenue Growth shows whether the company is expanding its market reach, gaining market share, or successfully launching new products.Net Income Growth demonstrates the company can convert that revenue into actual profits while managing costs effectively.
Look for steady, sustainable growth rather than erratic spikes. The best businesses compound earnings year after year, creating tremendous value for shareholders over time. Companies that can grow earnings faster than revenue are improving their profitability—a sign of operational excellence and competitive strength.
Year-over-year growth rates for revenue and earnings per share
Reading the Growth Rate Chart
This chart converts the absolute per-share figures into year-over-year percentage changes, making it easy to see whether growth is accelerating, decelerating, or reverting to trend — regardless of the company's absolute size.
Revenue per Share Growth (1-year, split-adjusted) measures how quickly the top line is expanding on a per-share basis. Sustained positive growth signals that the company continues to win customers and grow its addressable market.EPS Diluted Growth (1-year, split-adjusted) measures how quickly earnings are compounding for each shareholder. When EPS growth consistently outpaces revenue growth, operating leverage and margin expansion are at work.
Look for consistency, not just magnitude. A company that reliably grows EPS 10–15% per year is far more valuable than one that alternates between 50% spikes and deep contractions. Negative EPS growth during a period of positive revenue growth is a red flag — costs are rising faster than sales. Quarters where both lines converge near zero or go negative deserve close scrutiny.
How revenue converts to net income for the most recent annual period
Period Information
Report Type: Annual (10-K)
Period: Apr 2025 to Mar 2026
Revenue composition by disclosure category for the latest period
Patient services revenues generated by hospital inpatient care, including medical/surgical services, intensive care, cardiac care, diagnostic services and emergency services.
Patient services revenues generated by outpatient services provided by hospitals and outpatient facilities, including outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, physical therapy, diagnostic and imaging services, and radiation and oncology therapy.
Revenues from behavioral health services delivered through behavioral hospitals, inpatient, partial hospitalization and outpatient settings.
Revenues from rehabilitation services provided through rehabilitation hospitals and hospital rehabilitation units.
Revenues from ambulatory surgery centers and freestanding endoscopy centers for surgical procedures and related services.
Revenues from physician services reimbursed under fee schedules (Physician Fee Schedule) and related clinician services.
Revenues from home health agencies, hospices, outpatient physical therapy providers, home and community-based services providers and other ancillary and post-acute services.
Payments under government programs, including Medicare, Medicaid and TRICARE, for inpatient and outpatient services and for portions of deductible and coinsurance amounts of beneficiaries that are uncollectable.
Payments from managed care plans (including Medicare Advantage/Managed Medicare and managed Medicaid), private insurers, employer-sponsored plans and health plans offered through federal and state Exchanges.
State-directed, supplemental and disproportionate share hospital (DSH) payments under Medicaid and other state programs that are separate from base reimbursements.
Revenues from value-based and alternative payment arrangements, including accountable care organizations, bundled payment models and CMS Innovation Center demonstration projects (including programs that provide shared savings or require shared losses).
Management and administrative services provided by affiliates to health care facilities (explicitly described management services such as supply contracting, equipment purchasing/leasing, accounting, clinical systems, reimbursement assistance, construction planning, IT systems, legal counsel, human resources and internal audit).
Federal government programs and agencies as payers, specifically Medicare.
State governments and state-administered Medicaid programs as payers and sources of supplemental and state-directed payments.
Managed care plans, including Medicare Advantage plans (Managed Medicare), Medicaid managed care organizations (Managed Medicaid), HMOs and PPOs.
Private health insurers and other commercial managed care and employer-sponsored group purchasers of health care services.
Individual patients, including uninsured and self-pay patients who pay directly and patients with coinsurance, deductibles or other cost-sharing responsibilities.
International managed care and insurer entities for services provided in England.
Military health program (TRICARE) as a payer for active duty and eligible beneficiaries.
Physicians and other health care professionals as referral sources and as parties to employment, contractual and joint-venture arrangements.
Operates hospitals and other health care facilities in nineteen U.S. states and in England.
Health care facility footprint includes general acute care hospitals, behavioral hospitals, rehabilitation hospitals, freestanding ambulatory surgery centers and freestanding endoscopy centers across those jurisdictions.
Facilities and operations are concentrated in certain states, with explicit note of heavy concentration in Florida and Texas.
Delivery of services primarily through owned, managed or operated facilities, including general acute care hospitals, behavioral and rehabilitation hospitals, ASCs, freestanding emergency care facilities, urgent care facilities, walk-in clinics, physician practices, diagnostic and imaging centers, home health and hospice agencies, and other outpatient and ancillary sites.
Most ASCs operated through partnerships or limited liability companies with majority ownership typically held by an HCA affiliate.
Revenue realization through negotiated contracts with third-party payers (managed care contracts) that are typically negotiated for terms between one and three years.
Direct patient billing for uninsured and self-pay patients, including application of charity care policies and uninsured discounts where applicable.
Provider participation and billing under federal and state programs administered through Medicare Administrative Contractors and similar contractors for claim processing and audits.
Use of enterprise-level management services and national supply contracts provided by affiliates to support facility operations and purchasing.
Revenues are primarily reimbursement-based, derived from ongoing payer programs (Medicare, Medicaid, managed care plans, private insurers) and from ongoing patient service delivery at facilities, indicating a recurring reimbursement model tied to patient volumes and payer arrangements.
Managed care contracts have explicit multi-year terms indicating recurring contractual relationships with payers.
Certain payments are periodic or programmatic (e.g., state supplemental payments, DSH payments, value-based shared savings or repayments) and may be subject to annual or periodic approval or recalculation.
Revenue recognition and cash flows are affected by regulatory and administrative processes that include annual cost reports, prior authorization requirements, post-payment audits and reviews (including RACs, UPICs and other integrity contractors), and appeal processes, which can adjust amounts ultimately determined to be due.
Alternative payment models and CMS programs may provide performance-based or delayed payments (for example, shared savings paid after performance periods), reflecting both recurring and contingent payment characteristics.
Dependence on reimbursements from government payers (Medicare and Medicaid) and on managed care plans and private insurers for the majority of patient service payments; these programs and contracts are subject to regulatory changes, payment rate updates and policy shifts described in the filing.
Geographic concentration risk due to heavy concentration of facilities in specific states, explicitly including Florida and Texas, making operations sensitive to regulatory, economic, public health and environmental conditions in those states.
Dependence on negotiated managed care contracts and the ability to retain favorable contract terms; managed care contracts are explicitly negotiated and can affect volumes and reimbursement.
Reliance on physician referrals and relationships with employed and affiliated physicians; physicians may terminate affiliations at any time, and physician recruitment and retention are identified as important to utilization and competitive position.
Exposure to payer audits, administrative contractor transitions (MAC transitions) and integrity programs (RACs, UPICs), which can result in payment recoveries, denials and additional costs.
Dependency on state-administered supplemental and state-directed payment arrangements and on the availability and approval of those programs by CMS; these payments are subject to change and periodic CMS approval.
Competitive pressures from other hospitals, physician-owned facilities, not-for-profit and tax-supported entities, freestanding specialty providers and ASCs, which may affect patient volumes and contract negotiations.
Operational risk from compliance and regulatory frameworks (fraud and abuse laws, Stark Law, licensure, accreditation and EMTALA) that could materially affect reimbursement and ability to operate facilities if compliance failures occur.
Analyzing long-term margin stability and competitive positioning
HCA Healthcare, Inc.'s gross margin series is marked by large historical swings but has settled into low‑teens in the most recent years. After very high readings around 83–85% in 2017 and 2022–2023 and several negative observations in 2013–2015, the last two annual observations show gross margin of 12.1% for 2024 and a modest increase to 13.0% for 2025.
Operating margin is reported most recently for the 2024 year at -3.2%. Net profit margin series rises from mid‑single digits in the 2010s to 7.3% in 2020 and 11.8% in 2021; the latest available net margin observation is 11.8% for 2021.
The latest observed values are: Gross Margin 13.0% (period end 2025-12-31); Operating Margin -3.2% (period end 2024-12-31); Net Profit Margin 11.8% (period end 2021-12-31).
Understanding Profit Margins
Between Apr 2025 and Mar 2026, Hca Healthcare Inc converts every dollar of revenue through the following stages:
Sustainable competitive advantages reveal themselves through consistently superior profit margins over extended periods. Companies with durable economic moats maintain pricing power and operational efficiency that competitors struggle to match.
A sign of durable competitive advantage is earning sustained higher margins than competitors.Look for margins that remain stable or improve over time, especially during economic downturns. Declining margins may signal increasing competition, pricing pressure, or deteriorating business fundamentals.
Comparing reported earnings to actual cash generation
HCA Healthcare, Inc.'s trailing twelve-month net income shows a rising trend over the dataset, increasing from about $2.23B in early 2015 to $2.89B in 2016, then to $3.50B in 2019 and $3.75B in 2020, before a notable jump to $6.96B at year-end 2021. By contrast, reported trailing twelve-month operating cash flow in the available series is relatively flat, hovering in the $5.1B–$5.7B range from 2015 through early 2018 with a most recent reported level of $5.45B. The gap between net income and operating cash flow widens in the most recent comparable observations, with net income exceeding operating cash flow.
Most recent Net Income (TTM): $6.96B (period end 2021-12-31)
Most recent Operating Cash Flow (TTM): $5.45B (period end 2018-03-31)
The Earnings vs. Cash Flow Gap
Reported earnings (Net Income) doesn't always reflect actual cash generation. Companies use accrual accounting, which recognizes revenue when earned and expenses when incurred—not when cash actually changes hands. This creates timing differences and opportunities for accounting discretion that can mask underlying business health.
Net Income (the "earnings" number) can be influenced by non-cash items like depreciation, stock-based compensation, and changes in accounting estimates.Operating Cash Flow, however, shows the actual cash the business generates from its core operations—a harder number to manipulate.
What to Look For
Key Insight: Companies with durable competitive advantages typically show operating cash flow that meets or exceeds net income over time, demonstrating they convert accounting profits into actual cash that can be returned to shareholders or reinvested in the business.
Measuring management's efficiency at generating profits from shareholder capital
HCA Healthcare, Inc.'s trailing twelve-month return on equity was relatively steady in the historical sample, generally clustering between about 7.9% and 10.3% across the 2015–2019 and 2016 quarterly observations. ROE remained near the low end of that range through 2019 (7.9%) and 2020 (8.4%), indicating limited variation in the earlier periods shown.
The most notable inflection is a pronounced increase in the latest period: ROE rose from 8.4% for the year ending to 14.1% for the year ending , a 5.7 percentage-point increase. The most recent trailing twelve-month ROE observed was 14.1% as of .
The Gold Standard of Profitability
Return on Equity (ROE) is a powerful measure of how effectively a company's management is using the money shareholders have invested. Calculated by dividing Net Income by Shareholders' Equity, it reveals how much profit is generated for every dollar of equity capital.
A consistently high ROE (typically above 15-20%) is often the signature of a "quality" business with a durable competitive advantage. It indicates that the company can generate high returns on its own capital, which it can then reinvest at these high rates to compound value over time.
What to Look For:
How the company generates and deploys its cash
HCA Healthcare, Inc.'s financing cash flow is consistently negative in the provided history and shows a clear recent increase in outflow. Financing CF TTM was reported at -$4.58B for the 2024 period and moves to -$8.55B for the period ending 2025-12-31, representing the most pronounced inflection in the dataset; earlier financing TTM figures ranged from -$2.00B (2013) to about -$6.67B (2021).
Operating cash flow TTM values in the dataset are limited to 2015–2018, where operating CF was relatively stable in the $4.7B–$5.7B range, with the latest reported operating CF TTM of $5.45B (period ending 2018-03-31).
Investing cash flow TTM is not present in the provided data.
Understanding Company Strategy
Capital allocation refers to how management decides to spend and invest the company's cash. Analyzing the three primary categories of cash flow reveals a company's true operational strategy:
What to look for: Is the company bootstrapping (funding growth solely from operating cash)? Are they borrowing to fund aggressive expansion or dividends? Or are they capital raising by issuing new shares, potentially diluting your ownership? A healthy, mature company typically generates strong operating cash, moderately invests in growth, and returns the surplus to shareholders through financing activities.
Net assets attributable to each share — the accounting floor of intrinsic value
Why Book Value per Share Matters
Book value per share is the net worth of the company — total assets minus total liabilities — divided by shares outstanding (split-adjusted). It represents the theoretical liquidation value per share if every asset were sold and every liability repaid at balance-sheet carrying values. It is the accounting foundation upon which much of equity valuation is built.
A steadily rising book value per share is one of the most reliable signals of compounding wealth creation. It means the company is retaining earnings and building net worth faster than it is returning capital or eroding it. Warren Buffett famously tracked Berkshire Hathaway's book value per share for decades as his primary measure of intrinsic value growth.
Context is essential. Asset-heavy businesses (banks, manufacturers, utilities) should be judged by book value more directly than asset-light businesses (software, consumer brands), where intangible assets like intellectual property and customer loyalty may far exceed their balance-sheet carrying values. A company trading at a large premium to book value is not necessarily overvalued — it may simply possess competitive advantages that accounting rules do not capture. Conversely, a declining book value per share — especially over multiple years — is a serious warning sign of capital destruction.
How much of the company is financed by debt versus shareholders' equity
Reading the Debt-to-Equity Ratio
The debt-to-equity (D/E) ratio compares total financial debt to shareholders' equity. A ratio of 1.0 means the company has borrowed one dollar for every dollar of equity; a ratio of 2.0 means it has borrowed twice as much as it owns. Financial leverage amplifies both returns and risk: in good times, debt turbocharges equity returns; in bad times, it accelerates losses and can threaten solvency.
Trends matter more than a single number. A rising D/E ratio can mean the company is taking on debt to fund growth — potentially value-creating if returns exceed the cost of capital. But it can also mean equity is being eroded through losses or that the business is borrowing simply to sustain operations. A falling D/E ratio generally reflects strengthening financial health: earnings are being retained, debt maturities are being paid down, or both.
Industry norms vary enormously. Capital-intensive sectors (utilities, real estate, financials) routinely carry high D/E ratios that would be alarming in, say, a technology company. Always compare against sector peers. As a rough rule of thumb, a D/E above 2× in a cyclical business warrants careful scrutiny of interest coverage and refinancing risk.
Short-term liquidity — can the company cover its near-term obligations?
Liquidity: Can the Business Pay Its Bills?
The current ratio is calculated as current assets divided by current liabilities. A ratio of 1.5 means the company has $1.50 of short-term assets — cash, receivables, inventory — for every $1.00 of obligations due within the next twelve months. It is the most direct measure of near-term financial resilience: can the business meet its obligations without needing to raise new capital or sell long-term assets at a discount?
A ratio above 1.0 is generally healthy, meaning current assets exceed current liabilities. A ratio consistently above 2.0 may indicate the company is holding excess cash or inventory that could be deployed more productively. A ratio below 1.0 is a warning sign — the company is relying on future cash generation or external financing to cover its near-term obligations, which is manageable in normal conditions but dangerous during a downturn.
Trends and context matter.A declining current ratio isn't always alarming — highly efficient businesses (e.g., large retailers with reliable daily cash flows) often run leaner balance sheets intentionally. Conversely, a rapidly rising current ratio can signal slowing sales causing inventory to build, or customers taking longer to pay. Always compare the trend against industry peers and cross-reference with the cash flow statement to assess whether the business is genuinely liquid or just holding non-cash current assets.
How much the market is paying for each dollar of company earnings
HCA Healthcare, Inc.'s trailing twelve-month P/E has moved lower in the most recent reported years, falling from 10.3x at 2020-12-31 (and 9.9x at 2019-12-31) to 8.7x at 2021-12-31. That recent sequence shows a contraction in the multiple over the last one-to-two reporting years in the dataset.
Over the full history provided, the P/E has ranged from a low of 2.1x at 2011-12-31 to highs near 10.0x (2015-06-30) and 10.3x (2020-12-31), with a notable trough at 6.1x on 2016-12-31 amid volatility in 2015–2016. The most recent Price-to-Earnings ratio was 8.7x as of 2021-12-31.
What Is the PE Ratio?
The Price-to-Earnings (PE) ratio is one of the most widely used valuation metrics in investing. It divides the current stock price by the company's earnings per share (EPS), revealing how much investors are willing to pay for each dollar of earnings. A high PE can signal that the market expects strong future growth, while a low PE may suggest undervaluation—or reflect genuine concerns about the company's prospects.
Context matters:PE ratios vary significantly across industries. High-growth technology companies routinely trade at PE ratios above 30x or 40x, while mature, low-growth sectors like utilities or financials often trade closer to 10–15x. Always compare a company's PE to its own history and its industry peers, not just an absolute number.
What to Look For:
Key Insight:The PE ratio is a snapshot of market sentiment and expectations. Tracking it over time alongside earnings trends reveals whether the market's valuation has expanded or contracted—and whether that change is justified by fundamentals.